Accordingly, treatment of mammospheres from the luminal-B (but not the luminal-A) breast cancer patient with iadademstat significantly reduced the expression of SOX2, likely indicating a selective targeting of SOX2-driven CSC. This evidence concerns the gene SOX2 and breast carcinoma.